Plaque-adaptive flexible film dosimetry system for Ru-106 plaque brachytherapy commissioning and quality assurance.
New flexible film dosimeter matched reference doses within 3% for Ru-106 plaques.
Plaque-adaptive flexible film dosimetry system for Ru-106 plaque brachytherapy commissioning and quality assurance.
Ruthenium-106 (Ru-106) plaque brachytherapy is an established treatment modality for choroidal melanoma that delivers localized beta radiation while sparing surrounding ocular structures.
This study aimed to assess the feasibility and dosimetric accuracy of a plaque-adaptive flexible film dosimeter (PFD) for planar and central axis (central axis) dose measurements in Ru-106 plaque brachytherapy.
The PFD consisted of an active layer of lithium salt of pentacosa-10,12-diynoic acid (LiPCDA) enclosed between upper and lower silicone sheets.
measured doses landed within about 3% of true values on average
In the high-dose central region, the mean differences for CCA, COB, and CIB were 2.1% ± 0.8%, 2.1% ± 0.8%, and 2.2% ± 0.7%, respectively.
Central axis dose profiles measured with a microDiamond detector differed by 0.89% ± 0.58%.
Total dose uncertainty ranged from 4.43% at 0.3 Gy to 4.19% at 2.4 Gy.
The PFD enabled accurate and high-resolution dose measurements on the curved surfaces of Ru-106 plaques.
Both planar and central axis measurements demonstrated strong agreement with manufacturer-certified reference data across all plaque types.
This system offers a practical and reproducible solution for commissioning and quality assurance in Ru-106 plaque brachytherapy, supporting its clinical integration for choroidal melanoma treatment.